Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Joel Marrs to Cardiovascular Diseases

This is a "connection" page, showing publications Joel Marrs has written about Cardiovascular Diseases.

 
Connection Strength
 
 
 
0.634
 
  1. Marrs JC. Optimizing outcomes in patients with cardiovascular disease and chronic kidney disease. Am J Manag Care. 2011 Dec; 17 Suppl 15:S403-11.
    View in: PubMed
    Score: 0.221
  2. Marrs JC, Saseen JJ. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis. Pharmacotherapy. 2010 Aug; 30(8):823-9.
    View in: PubMed
    Score: 0.201
  3. Marrs JC, Kostoff MD. Discontinuation of Statins: What Are the Risks? Curr Atheroscler Rep. 2016 Jul; 18(7):41.
    View in: PubMed
    Score: 0.076
  4. Fosmire Rundgren EW, Anderson SL, Marrs JC. Evaluation of aspirin use in patients with diabetes receiving care in community health. Ann Pharmacother. 2015 Feb; 49(2):170-7.
    View in: PubMed
    Score: 0.067
  5. Marrs JC. Colesevelam for the management of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2009 Feb; 5(2):187-94.
    View in: PubMed
    Score: 0.045
  6. Wiggins BS, Dixon D, Bellone J, Gasbarro N, Marrs JC, Tran R. Key Articles and Guidelines in the Management of Dyslipidemia: 2019 Update. J Pharm Pract. 2020 Dec; 33(6):882-894.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)